Importance Synaptic loss is well established as the major structural correlate of cognitive
impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could
accelerate the development of disease-modifying treatments for AD. Synaptic vesicle
glycoprotein 2A is an essential vesicle membrane protein expressed in virtually all synapses
and could serve as a suitable target for synaptic density. Objective To compare hippocampal
synaptic vesicle glycoprotein 2A (SV2A) binding in participants with AD and cognitively …